SIRPA and neoplasm: Validation of a radiolabeled lead candidate, further referred as [64Cu]copper-SIRPα-nanobody ([64Cu]Cu-SIRPα-Nb), demonstrated its suitability for monitoring the dynamics of myeloid cells in a preclinical tumor mouse model (22).